GLP-1 based therapy for type 2 diabetes

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 1-2, 2006, Pages 96-108

  Arulmozhi, D K ^a   Portha, B ^b  

^a LUPIN LIMITED   (India)

^b CNRS   (France)

Author keywords

DPP IV; Exenatide; GLP 1; Type 2 diabetes; Vildagliptin

Indexed keywords

3 AMINO 1 [5,6,7,8 TETRAHYDRO 3 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7 YL] 4 (2,4,5 TRIFLUOROPHENYL) 1 BUTANONE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBUGON; AMINOPEPTIDASE; BIM 51077; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FF 1; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GSK 23A; GW 229A; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; NN 7201; OP 86753401; PHOSPHORUS 32; PHX 1004; PSN 9301; PT 630; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; T 6666; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE; VILDAGLIPTIN; ZP 10;

ABSENCE OF SIDE EFFECTS; ALOPECIA; ANEMIA; BLOODY DIARRHEA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG METABOLISM; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; HEADACHE; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; INTESTINE CELL; L CELL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SPLENOMEGALY; STOMACH EMPTYING; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS; RECEPTORS, GLUCAGON;

EID: 33644902945     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.01.003     Document Type: Review

References (110)

1. C.A. Abbot, D.M. Yu, E. Woollatt, G.R. Sutherland, G.W. McCaughan, and M.D. Gorrell Cloning, expression and chromosal localization of a novel human dipeptidyl peptidase (DPP) IV homolog DPP8 Eur. J. Biochem. 267 2000 6140 6150
2. E.J. Abraham, C.A. Leech, J.C. Lin, H. Zulewski, and J.F. Habener Insulinotropic hormone glucagon-like peptide-1 induced differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells Endocrinology 143 2002 3152 3161
3. B. Ahrén, M. Landlin-Olesson, P.A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J. Clin. Endocrinol. Metab. 89 2004 2078 2084
4. B. Ahrén, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diab. Care 27 2004 2874 2880
5. B. Ahrén, and G. Pacini Glucagon-like peptide-1 stimulates insulin secretion and glucose effectiveness in mice Am. J. Physiol. 277 1999 E996 E1004
6. B. Ahrén, and O. Schimitz GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes Horm. Metab. Res. 36 2004 867 876
7. B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J.W. Eriksson, S. Dickinson, and D. Holmes Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diab. Care 25 2002 869 875
8. B. Ahrén Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes Drug Discov. Today 1 2004 207 212
9. B. Ahrén Inhibition of dipeptidyl peptidase-4 (DPP-4)-a novel approach to treat type 2 diabetes Curr. Enzym. Inhibit. 1 2005 65 73
10. Y. Anini, and P.L. Brubaker Role of leptin in the regulation of glucagon-like peptide-1 secretion Diabetes 52 2003 252 259
11. Y. Anini, T. Hansotia, and P.L. Brubaker Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats Endocrinology 143 2002 2420 2426
12. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037
13. G.I. Bell, R. Sanchez-Pescador, P.J. Laybourn, and R.C. Najarian Exon duplication and divergence in the human preproglucagon gene Nature 304 1983 368 371
14. M. Bloom, J. Block, A. Duttaroy, K. Grzegorzewski, P. Moor, Y. Ou, S. Wojcik, X. Zhou, and A. Bell Albugon fusion protein: a long acting analogue of GLP-1 that provides lasting antidiabetic effect in animals Diabetes 52 Suppl. 1 2003 A112 (Abstract)
15. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
16. M. Bouras, J.F. Huneau, C. Leuengo, C. Erlanson-Alberstsson, and D. Tome Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases Peptides 16 1995 399 405
17. I. Brandt, J. Joossens, X. Chen, M.B. Maes, S. Scharpe, I.D. Meester, and A.M. Lambeir Inhibition of dipeptidyl peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2- carbonitrile) Biochem. Pharmacol. 70 2005 134 143
18. P.L. Brubaker, and Y. Anini Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagons-like peptide-2 Can. J. Physiol. Pharmacol. 83 2003 1005 1012
19. B.F. Burkey, L. Bolognese, B. Balkan, M. Mone, M. Russell, T.W. Hughes, and P.R. Wang Acute and chronic effects of the incretin enhancer vildagliptin in insulin resistant rats J. Pharmacol. Exp. Ther. 315 2005 688 695
20. C.G. Caldwyll, P. Chen, J. He, E.R. Parmee, B. Leiting, F. Marsilio, R.A. Patel, J.K. Wu, G.J. Eiermann, A. Petrol, H. He, K.A. Lyons, N.A. Thornberry, and A.E. Waber Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 1265 1268
21. H.R. Davis, D.E. Mullins, J.M. Pines, L.M. Hoos, C.F. France, D.S. Compton, M.P. Graziano, E.J. Sybertz, C.D. Strader, and M. Van Heek Effect of chronic central administration of glucagon-like peptide-1(7-36) amide on food consumption and body weight in normal and obese rats Obes. Res. 6 1998 147 156
22. C.F. Deacon, L.B. Knudsen, K. Madsen, F.C. Wiberg, O. Jacobsen, and J.J. Holst Dipeptidylpeptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity Diabetologia 41 1998 271 278
23. H.U. Demuth, C.H.S. McIntosh, and R.A. Pederson Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors Biochim. Biophys. Acta 1751 2005 33 44
24. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diab. Care 26 2003 2929 2940
25. H.C. Fehmann, R. Goke, and B. Goke Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide Endocr. Rev. 16 1995 390 410
26. H.C. Fehmann, and J. Habener Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma bTC-1 cells Endocrinology 130 1992 159 166
27. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J. Clin. Invest. 101 1998 515 520
28. J.F. Gautier, E. Sobngwi, and C. Salaün-Martin Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes Diab. Metab. 31 2005 233 242
29. N. Ginnoukakis CJC1311 ConjuChem Curr. Opin. Invest. Drugs 4 2003 1245 1249
30. R. Goke, P.J. Larsen, J.D. Mikkelsen, and S.P. Skeikh Distribution of GLP-1 binding sites in the rat brain: evidence that exending is ligand of brain GLP-1 sites Eur. J. Neurosci. 7 1995 2968 2978
31. F.M. Gribble, and F. Reimann Pharmacological modulation of K(ATP) channels Biochem. Soc. Trans. 30 2002 333 339
32. E. Grouzmann, E. Comoy, P. Walker, M. Burnier, C. Bohuon, B. Waeber, and H. Brunner Production and characterization of anti-neuropeptide Y monoclonal antibodies Hybridoma 11 1992 409 424
33. J.P. Gutzwiller, B. Goke, J. Drewe, P. Hildebrand, S. Ketterer, D. Handschin, R. Winterhalder, D. Conen, and C. Beglinger Glucagon-like peptide-1: a potent regulator of food intake in humans Gut 44 1999 81 86
34. H. Harder, L. Nielsen, D.T. Tu, and A. Astrup The effect of liraglutide, a long acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 25-h energy expenditure in type 2 diabetes Diab. Care. 27 2004 1915 1921
35. 1C greater than 6.0 Diabetes 53 Suppl. 2 2004 A128 (Abstract)
36. R.S. Heller, T.J. Kieffer, and J.F. Habener Insulinotropic glucagon-like peptide 1 receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas Diabetes 46 1997 785 791
37. G.A. Herman, P.L. Zhao, B. Dietrich, G. Golor, A. Schrodter, B. Keymuelen, K.C. Lasseter, M.S. Kipnes, D. Hilliard, M. Tanen, I. de Lepeleire, C. Cillissen, C. Stevens, W. Tanaka, K.M. Gottesdiener, and J.A. Wagner The DP-IV inhibitor MK-0431 enhances GLP-1 and reduces glucose following an OGTT in type 2 diabetes Diabetes 53 2004 A82 (Abstract)
38. G.A. Herman, C. Stevens, K. Van Dyck, A. Bergman, B. Yi, M. De Smet, K. Snyder, D. Hilliard, M. Tanen, W. Tanaka, A.Q. Wang, W. Zeng, D. Musson, G. Winchell, M.J. Davies, S. Ramael, K.M. Gottesdiener, and J.A. Wagner Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin. Pharmacol. Ther. 78 2005 675 688
39. C. Herrmann, R. Goke, G. Richter, H.C. Fehmann, R. Arnold, and B. Goke Glucagon-like peptide-1 and glucose dependant insulin-releasing polypeptide plasma levels in response to nutrients Digestion 56 1995 117 126
40. J.J. Holst Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors Adv. Exp. Med. Biol. 524 2003 263 279
41. J.J. Holst, and C.F. Deacon Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus Curr. Opin. Pharmacol. 4 2004 589 596
42. G.G.T. Holz, W.M. Kuhtreiber, and J.F. Habener Pancreatic β-cells are rencered glucose-competent by the insulinotropic hormone glucagons-like peptide-1(7-37) Nature 361 1993 362 365
43. V.K. Hopsu-Havu, and C.G. Glenner A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide Histochemie 7 1966 197 201
44. D. Hunziker, M. Hennig, and J.W. Peters Inhibitors of dipeptidyl peptidase IV - recent advances and structural views Curr. Top. Med. Chem. 5 2005 1623 1637
45. N. Imeryuz, B.C. Yegen, A. Bozkurt, T. Coskun, M.L. Villanueva- Penacarrillo, and N.B. Ulusoy Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am. J. Physiol. 273 1997 G920 G927
46. T. Karl, T. Hoffman, R. Pabst, and S. van Horstein Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences Physiol. Behav. 80 2003 123 134
47. T. Kato, T. Nagastu, K. Fukasawa, M. Harada, I. Nagatsu, and S. Sakakuibara Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase Biochim. Biophys. Acta 525 1978 417 422
48. U. Kettman, B. Humbel, and H.J. Holzhausen Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney Acta Histochem. 92 1992 225 227
49. J.G. Kim, L.L. Baggio, D.P. Bridon, J.P. Castaigne, M.F. Robitaille, L. Jette, C. Benquet, and D.J. Drucker Development and characterization of glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptors in vivo Diabetes 52 2003 751 759
50. Y.B. Kim, L.M. Kopcho, M.S. Kirby, L.G. Hamann, C.A. Weigelt, W.J. Metzler, and J. Marcinkeviciene Mechanism of gly-pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) Arch. Biochem. Biophys. 445 2006 9 18
51. T.J. Kieffer, and J.F. Habener The glucagons-like peptides Endocr. Rev. 25 1999 876 913
52. L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, N.L. Johansen, K. Madsen, F.Z. Pedersen, H. Thogersen, A. Wilken, and H. Agerso Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J. Med. Chem. 43 2002 1664 1669
53. L.B. Knudsen Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes J. Med. Chem. 47 2004 4128 4134
54. A.M. Lambeir, C. Durinx, P. Proost, J. van Damme, S. Scharpe, and I. De Meester Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion FEBS Lett. 507 2001 327 330
55. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrol, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994
56. S.L. Lautar, C. Rojas, B.S. Slusher, K.M. Wozniak, Y. Wu, A.G. Thomas, D. Waldon, W. Li, D. Ferraris, and S. Belyakov DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice Brain Res. 1048 2005 177 184
57. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 2003 471 478
58. J.R. Lindsay, N.A. Duffy, A.M. McKillop, J. Ardill, F.P.M. O'Harter, P.R. Flatt, and P.M. Bell Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes Diab. Med. 22 2005 654 657
59. M. Lu, M.B. Wheeler, X.H. Leng, and A.E.D. Boyd The role of the free cytosolic calcium level in β-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide-1(7-37) Endocrinology 132 1993 94 100
60. K. Ludwig, S. Yan, H. Fan, W. Reutter, and C. Bottcher The 3D structure of rat DPPIV/CD26 as obtained by cryo-TEM and single particle analysis Biochim. Biophys. Res. Commun. 304 2003 73 77
61. C.G. MacInstosh, M. Horowitz, M.A. Verhagen, A.J. Smout, J. Wishart, H. Morris, E. Goble, J.E. Moreley, and I.M. Chapman Effect of small intestinal nutrient infusion on appetite gastrointestinal hormone release, and gastric myoelectrical activity in young and older men Am. J. Gastroenterol. 96 2001 997 1007
62. S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, D.R. Matthews NN2211-1310 International Study Group Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) Diab. Care 27 2004 1335 1342
63. S. Majsov, G. Henrich, I.B. Wilson, M. Ravazzola, L. Orci, and J.F. Habner Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing J. Biol. Chem. 261 1986 11880 11889
64. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierrers, P.F. Nielsen, U. Ribel, T. Watanabe, D.J. Drucker, and N. Wagtmann Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. U.S.A. 97 2000 6874 6879
65. A. Mari, W.M. Sallas, Y.L. He, C. Watson, M. Ligueros-Saylan, B.E. Dunning, C.F. Deacon, J.J. Holst, and J.E. Foley Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed β-cell function in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 90 2005 4888 4894
66. J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, W.E. Schmidt, and M.A. Nauck Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 88 2003 2719 2725
67. R. Mentlein Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs Expert. Opin. Investig. Drugs 14 2005 57 64
68. R. Mentlein, P. Dahms, D. Grandt, and R. Kruger Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV Regul. Pept. 49 1993 133 144
69. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9 24
70. H.J. Mest, and R. Mentlein Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes Diabetologia 48 2005 616 620
71. Y. Misumi, Y. Hyashi, F. Arakawam, and Y. Ikehara Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface Biochim. Biophys. Acta 1131 1992 333 336
72. H. Mitani, M. Takimoto, T.E. Hughes, and M. Kimura Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity Jpn. J. Pharmacol. 88 2002 442 450
73. S. Mojsov, G.C. Weir, and J. Habener Insulinotropin: glucagon-like peptide-1(7-37) co-encoded in the glucagon gene is potent stimulator of insulin release in the perfused rat pancreas J. Clin. Invest. 79 1987 616 619
74. A.H. Mokdad, E.S. Ford, B.A. Bowman, W.H. Dietz, F. Vinicor, V.S. Bales, and J.S. Marks Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 JAMA 289 2003 76 79
75. M. Nauck, F. Stockman, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin dependant) diabetes Diabetologia 29 1986 46 52
76. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycemia by exogenous glucagons-like peptide 1(6-36) amide in type 2 (non-insulin dependent) diabetic patients Diabetologia 36 1993 741 744
77. M.A. Nauck, J.J. Meier, and W. Creutzfeld Incretins and their analogues as new antidiabetic drugs Drugs News Perspect. 16 2003 413 422
78. M.A. Nauck, Sauerwald, R. Ritzel, J.J. Holst, and W. Schmiegel Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure Diab. Care 21 1998 1925 1931
79. M.A. Nauck, D. Wollschlager, J. Werner, J.J. Holst, C. Orskov, W. Creutzfeldt, and B. Willms Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM Diabetologia 39 1996 1546 1553
80. I. Naush, R. Mentlein, and E. Heymann The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta Biol. Chem. Hoppe Seyler 371 1990 1113 1118
81. L.L. Nielsen, A.A. Young, and D.G. Parkes Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul. Pept. 117 2004 77 88
82. L. Nielsen Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes Drug Discov. Today 10 2005 703 710
83. C. Olsen, and N. Wagtmann Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV Gene 299 2002 185 193
84. C. Orskov, L. Rabenhoj, A. Wettergren, H. Kofod, and J.J. Holst Tissue and plasma concentrations of amidated and glycine-extended glucagons-like peptide 1 in humans Diabetes 43 1994 535 539
85. C. Orskov, A. Wettergren, and J.J. Holst Biological effects and metabolic rates of glucagon-like peptide 1(7-36)amide and glucagon-like peptide 1(7-37) in healthly subjects are indistinguishable Diabetes 42 1993 658 661
86. R. Perfetti, J. Zhou, M.E. Doyle, and J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic duodenum homeobox-1 expression an increase endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600 4605
87. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H. McIntosh, and R.A. Pederson Long-term treatment with dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 2002 943 950
88. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, C.H.S. McIntosh, and R.A. Pederson Long-term treatment with the dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in VDF Zucker rat: a euglycemia-hyperinsulinemic clamp study Diabetes 51 2002 2677 2683
89. P. Proost, U. De Meester, D. Schols, S. Struyf, A.M. Lambeir, A. Wuyts, G. Opdenkker, E. De Clerq, S. Scharpe, and J. van Damme Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection J. Biol. Chem. 273 1998 7222 7227
90. P. Proost, S. Struyf, D. Schols, G. Opdenakker, S. Sozzani, P. Allavena, A. Mantovani, K. Augustyns, G. Bal, A. Haemers, A.M. Lambeir, S. Schrape, J. van Damme, and U. De Meester Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction J. Biol. Chem. 274 1999 3988 3993
91. J. Rahfeld, M. Schierhorn, B. Hatrodt, K. Neubert, and J. Heins Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim. Biophys. Acta 1076 1991 314 316
92. U. Ribel, M.O. Larsen, B. Rolin, R.D. Carr, M. Wilken, J. Sturis, L. Westergaard, C.F. Deacon, and B.L. Knudsen NN2211: a long acting glucagon-like peptide-1 derivative with anti-diabetic effects glucose-intolerant pigs Eur. J. Pharmacol. 451 2002 217 225
93. S. Ristic, S. Byiers, J. Foley, and D. Holmes Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response Diab. Obes. Metab. 7 2005 692 698
94. A.S. Rocca, and P.L. Brubaker Role of the vagus nerve in mediating proximal nutrient induced glucagon-like peptide-1 secretion Endocrinology 140 1999 1687 1694
95. B. Rolin, M.O. Larsen, C.F. Gotfredsen, C.F. Deacon, R.D. Carr, M. Wilken, and L.B. Knudsen The long acting GLP-1 derivative NN2211 meliorates glycemia and increase beta-cell mass in diabetic mice Am. J. Physiol. 283 2002 E745 E752
96. J.S. Rosenblum, and J.W. Kozarich Prolyl peptidases: a serine protease subfamily with high potential for drug discovery Curr. Opin. Chem. Biol. 7 2003 496 504
97. J. Sturis, C.F. Gotfredsen, J. Romer, B. Rolin, U. Ribel, C.L. Brand, M. Wilken, K. Wassermann, C.F. Deacon, R.D. Carr, and L.B. Knudsen GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics Br. J. Pharmacol. 140 2003 123 132
98. B. Sudre, P. Broqua, R.B. White, D. Ashworth, D.M. Evans, R. Haigh, J.L. Junien, and M.L. Aubert Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats Diabetes 51 2002 1461 1469
99. K. Takasaki, T. Nakajaima, K. Ueno, Y. Nomoto, and K. Higo Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats J. Pharmacol. Sci. 95 2004 291 293
100. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russel, and T.E. Hughes 1-[[(3-Hydroxy-1-adamantyl- amino]acetyl]2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors with antihyperglycemic properties J. Med. Chem. 46 2003 2774 2789
101. T. Vilsboll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced post-prandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609 611
102. E. Wargent, C. Stocker, P. Augstein, P. Heinke, A. Meyer, T. Hoffmann, A. Subramaniam, M.V. Sennitt, H.U. Demuth, J.R.S. Arch, and M.A. Cawthorne Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone Diab. Obes. Metab. 7 2005 170 181
103. S. Wen Lack of immunogenity of CJC1311, a long acting GLP-1 analogue for the treatment of type 2 diabetes Diabetes 53 Suppl. 2 2004 A151 (Abstract)
104. P.E. Wiedeman, and J.M. Trevillyan Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes Curr. Opin. Invest. Drugs 4 2003 412 420
105. S.M. Winzell, and B. Ahrén The high-fat fed mouse: a model for studying the mechanisms and treatment of impaired glucose tolerance and type 2 diabetes Diabetes 53 Suppl. 3 2004 S215 S219
106. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
107. 2+ channel activity Endocrinology 133 1993 1685 1692
108. H. Yamamoto, T. Kishi, C.E. Lee, B.J. Choi, H. Fang, A.N. Hollenberg, D.J. Drucker, and J.K. Elmquist Glucagon-like peptide-1 responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites J. Neurosci. 23 2003 2939 2946
109. J. Zhou, X. Wang, M.A. Pineyro, and J.M. Egan Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358 2366
110. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787